MA37691A1 - 5-amino[1,4]thiazines comme inhibiteurs de bace1 - Google Patents

5-amino[1,4]thiazines comme inhibiteurs de bace1

Info

Publication number
MA37691A1
MA37691A1 MA37691A MA37691A MA37691A1 MA 37691 A1 MA37691 A1 MA 37691A1 MA 37691 A MA37691 A MA 37691A MA 37691 A MA37691 A MA 37691A MA 37691 A1 MA37691 A1 MA 37691A1
Authority
MA
Morocco
Prior art keywords
thiazines
amino
bace1 inhibitors
present
compounds
Prior art date
Application number
MA37691A
Other languages
English (en)
Other versions
MA37691B1 (fr
Inventor
Hans Hilpert
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37691A1 publication Critical patent/MA37691A1/fr
Publication of MA37691B1 publication Critical patent/MA37691B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La présente invention concerne des composés de formule i présentant une activité inhibitrice de bace1, leur préparation, des compositions pharmaceutiques les contenant et leur utilisation comme substances thérapeutiquement actives. Les composés actifs de la présente invention sont utiles dans le traitement thérapeutique et/ou prophylactique de, par exemple, la maladie d'alzheimer.
MA37691A 2012-05-24 2014-12-24 5-amino[1,4]thiazines comme inhibiteurs de bace1 MA37691B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12169353 2012-05-24
PCT/EP2013/060352 WO2013174781A1 (fr) 2012-05-24 2013-05-21 5-amino[1,4]thiazines comme inhibiteurs de bace1

Publications (2)

Publication Number Publication Date
MA37691A1 true MA37691A1 (fr) 2016-03-31
MA37691B1 MA37691B1 (fr) 2016-11-30

Family

ID=48534350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37691A MA37691B1 (fr) 2012-05-24 2014-12-24 5-amino[1,4]thiazines comme inhibiteurs de bace1

Country Status (22)

Country Link
US (1) US9273042B2 (fr)
EP (1) EP2855469B1 (fr)
JP (1) JP6251249B2 (fr)
KR (1) KR20150014934A (fr)
CN (1) CN104334554B (fr)
AU (1) AU2013265376B2 (fr)
BR (1) BR112014028813A2 (fr)
CA (1) CA2872179A1 (fr)
CL (1) CL2014003123A1 (fr)
CO (1) CO7131369A2 (fr)
CR (1) CR20140495A (fr)
EA (1) EA026004B1 (fr)
HK (1) HK1201261A1 (fr)
IL (1) IL235681A (fr)
MA (1) MA37691B1 (fr)
MX (1) MX2014013839A (fr)
NZ (1) NZ702254A (fr)
PE (1) PE20150021A1 (fr)
PH (1) PH12014502541A1 (fr)
SG (1) SG11201407575PA (fr)
UA (1) UA113438C2 (fr)
WO (1) WO2013174781A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012298983A1 (en) * 2011-08-22 2014-02-27 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use
US9556135B2 (en) 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
WO2015017407A1 (fr) 2013-07-30 2015-02-05 Amgen Inc. Composés de dioxyde d'amino-thiazine bicycliques pontés en tant qu'inhibiteurs de bêta-sécrétase
WO2015038446A1 (fr) * 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. Dioxydes d'iminothiazine spiro-c5 utilisés comme inhibiteurs de bace, compositions, et leur utilisation
JP6554547B2 (ja) * 2014-11-03 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤
CR20170426A (es) 2015-03-20 2017-10-23 Hoffmann La Roche Inhibidores de bace 1
WO2017025491A1 (fr) * 2015-08-12 2017-02-16 F. Hoffmann-La Roche Ag Inhibiteurs de bace1
KR20210003872A (ko) 2018-04-27 2021-01-12 시오노기 앤드 컴파니, 리미티드 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체
CN110467611B (zh) * 2018-05-11 2022-09-27 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221579A1 (en) * 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) * 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
BR112013026341A2 (pt) * 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
AU2012298983A1 (en) * 2011-08-22 2014-02-27 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use

Also Published As

Publication number Publication date
SG11201407575PA (en) 2014-12-30
AU2013265376B2 (en) 2017-07-20
CO7131369A2 (es) 2014-12-01
CR20140495A (es) 2014-12-01
CA2872179A1 (fr) 2013-11-28
UA113438C2 (xx) 2017-01-25
KR20150014934A (ko) 2015-02-09
AU2013265376A1 (en) 2014-11-13
JP2015517548A (ja) 2015-06-22
PH12014502541B1 (en) 2015-01-21
IL235681A0 (en) 2015-02-01
EA026004B1 (ru) 2017-02-28
IL235681A (en) 2017-10-31
US9273042B2 (en) 2016-03-01
MX2014013839A (es) 2015-02-04
US20150141413A1 (en) 2015-05-21
EA201492097A1 (ru) 2015-04-30
NZ702254A (en) 2016-08-26
EP2855469B1 (fr) 2019-06-19
MA37691B1 (fr) 2016-11-30
PH12014502541A1 (en) 2015-01-21
PE20150021A1 (es) 2015-01-28
CN104334554A (zh) 2015-02-04
EP2855469A1 (fr) 2015-04-08
HK1201261A1 (en) 2015-08-28
CN104334554B (zh) 2017-10-31
JP6251249B2 (ja) 2017-12-20
WO2013174781A1 (fr) 2013-11-28
BR112014028813A2 (pt) 2017-06-27
CL2014003123A1 (es) 2015-02-27

Similar Documents

Publication Publication Date Title
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA38556A1 (fr) Inhibiteurs de bace1
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA35576B1 (fr) Nouveaux composés
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
MA41179A (fr) Composés inhibiteurs de parg
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA38280A1 (fr) Composes 1,2,3,4-tetrahydroisoquinoleine substitues inhibiteurs de la proteine arginine-methyltransferase 5
FR3012811B1 (fr) Oligopeptides et leurs utilisations